PE20120418A1 - DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP) - Google Patents
DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)Info
- Publication number
- PE20120418A1 PE20120418A1 PE2011001360A PE2011001360A PE20120418A1 PE 20120418 A1 PE20120418 A1 PE 20120418A1 PE 2011001360 A PE2011001360 A PE 2011001360A PE 2011001360 A PE2011001360 A PE 2011001360A PE 20120418 A1 PE20120418 A1 PE 20120418A1
- Authority
- PE
- Peru
- Prior art keywords
- parp
- halogen
- adp
- polymerase
- poly
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 2
- -1 CARBONYLOXY Chemical class 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: t ES 1-2; X ES O, S, ENTRE OTROS; R1 ES H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R2 ES H, HALOGENO, TIO, HIDROXI, ENTRE OTROS; R3 ES H, CARBONILOXI, ALCOXI C1-10, CARBONILO, AMINO, ENTRE OTROS; R4 ES H, HALOGENO, NITRO, CIANO, HIDROXI, CARBONILOXI, ENTRE OTROS; R5 ES H, HALOGENO, NITRO, CIANO, ALCOXI C1-10, ARILOXI C4-12, ENTRE OTROS; R6 ES H, CARBONILOXI, AMINO, ALQUILAMINO, ENTRE OTROS; R7 ES H, HALOGENO, NITRO, CIANO, CARBONILOXI, ALCOXI C1-10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-3-((4-(4-CLOROFENIL)PIPERAZIN-1-IL)-6a,7,8,9-TETRAHIDROPIRIDO[3,2-e]PIRROLO[1,2-a]PIRAZIN-6(5H)ONA; (S)-4-(4-((6-OXO-5,6,6a,7,8,9-HEXAHIDROPIRIDO[3,2-e]PIRROLO[1,2-a]PIRAZIN-3-IL)METIL)PIPERAZIN-1-IL)BENZONITRILO; ENTRE OTROS. DICHO COMPUESTO ES INHIBIDOR DE POLI(ADP-RIBOSA)POLIMERASA(PARP) UTIL EN EL TRATAMIENTO DE DE ENFERMEDADES, DESORDENES Y CONDICIONES RELACIONADAS CON LA ACTIVIDAD DEL PARP TALES COMO CANCER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14674009P | 2009-01-23 | 2009-01-23 | |
| US22887909P | 2009-07-27 | 2009-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120418A1 true PE20120418A1 (es) | 2012-05-04 |
Family
ID=42271897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001360A PE20120418A1 (es) | 2009-01-23 | 2010-01-21 | DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP) |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US7928105B2 (es) |
| EP (1) | EP2389379A1 (es) |
| JP (1) | JP5567599B2 (es) |
| KR (1) | KR101779137B1 (es) |
| CN (1) | CN102341394B (es) |
| AU (1) | AU2010206744B2 (es) |
| BR (1) | BRPI1007358A2 (es) |
| CA (1) | CA2750106A1 (es) |
| CL (1) | CL2011001754A1 (es) |
| CO (1) | CO6410305A2 (es) |
| CR (1) | CR20110452A (es) |
| DO (1) | DOP2011000237A (es) |
| EA (1) | EA020301B1 (es) |
| EC (1) | ECSP11011284A (es) |
| IL (1) | IL213993A (es) |
| MA (1) | MA33053B1 (es) |
| MX (1) | MX2011007741A (es) |
| MY (1) | MY152386A (es) |
| NZ (1) | NZ594322A (es) |
| PE (1) | PE20120418A1 (es) |
| SG (1) | SG172958A1 (es) |
| TN (1) | TN2011000339A1 (es) |
| WO (1) | WO2010085570A1 (es) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085570A1 (en) | 2009-01-23 | 2010-07-29 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| JP6022442B2 (ja) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 男性用避妊組成物および使用方法 |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| CN103037865B (zh) | 2010-05-14 | 2014-10-29 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的化合物 |
| TR201814710T4 (tr) * | 2011-09-30 | 2019-01-21 | C&C Res Lab | Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı |
| AU2013209394A1 (en) | 2012-01-20 | 2014-08-28 | Dennis Brown | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
| EP2935261A1 (de) * | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| CN103923088B (zh) * | 2013-01-11 | 2016-09-07 | 上海汇伦生命科技有限公司 | 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用 |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| HK1221721A1 (zh) * | 2013-07-09 | 2017-06-09 | Bayer Pharma Aktiengesellschaft | Bet蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物 |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| EP3099696A4 (en) * | 2014-01-31 | 2017-07-05 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| KR102310128B1 (ko) * | 2014-07-14 | 2021-10-06 | 주식회사 포스코 | 트리아진-피페라진 골격을 갖는 알파-헬릭스 유사체 및 이의 제조방법 |
| BR112017002369A2 (pt) | 2014-08-08 | 2017-12-05 | Dana Farber Cancer Inst Inc | derivados de diazepana e usos dos mesmos |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US10881668B2 (en) | 2015-09-11 | 2021-01-05 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
| CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| US11096909B2 (en) | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| EP3267192B1 (en) * | 2016-07-07 | 2020-08-19 | Alpha M.O.S. | Gas chromatograph comprising metal oxide sensors |
| CN106883232B (zh) * | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
| BR112022000534A2 (pt) * | 2019-07-19 | 2022-05-10 | Astrazeneca Ab | Inibidores de parp1 |
| CN111097386B (zh) * | 2019-12-26 | 2022-01-11 | 江苏大学 | 一种二维层状水稳定染料吸附剂及制备方法 |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| EP4328224A4 (en) * | 2021-04-22 | 2025-06-18 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| TW202302602A (zh) * | 2021-04-23 | 2023-01-16 | 大陸商四川海思科製藥有限公司 | 並環雜環衍生物及其在醫藥上的應用 |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| EP4392425A4 (en) * | 2021-08-27 | 2025-09-03 | Impact Therapeutics Shanghai Inc | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THEIR USE |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| CN118019740A (zh) * | 2021-09-30 | 2024-05-10 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| EP4410792A4 (en) * | 2021-09-30 | 2025-12-03 | Xizang Haisco Pharmaceutical Co Ltd | NITROGEN-CONTAINS HETEROCYCLIC DERIVATIVE FOR USE AS A PARP INHIBITOR AND ITS USE |
| US20240391937A1 (en) * | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| PE20241129A1 (es) | 2021-10-01 | 2024-05-24 | Xinthera Inc | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| TWI842210B (zh) * | 2021-11-19 | 2024-05-11 | 大陸商成都百裕製藥股份有限公司 | 選擇性parp1抑制劑及其應用 |
| WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023109521A1 (zh) * | 2021-12-17 | 2023-06-22 | 凯复(苏州)生物医药有限公司 | Parp抑制剂、包含其的药物组合物及其用途 |
| EP4464704A4 (en) * | 2022-01-13 | 2025-09-03 | Acerand Therapeutics Hong Kong Ltd | DERIVATIVE CONTAINING A PIPERAZINO RING, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR ITS PREPARATION AND USE THEREOF |
| KR102866565B1 (ko) | 2022-01-21 | 2025-10-02 | 신테라, 인크. | Parp1 저해제 및 이의 용도 |
| KR20240162104A (ko) * | 2022-03-11 | 2024-11-14 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도 |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| WO2023212219A1 (en) | 2022-04-28 | 2023-11-02 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| WO2024083201A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| EP4617272A1 (en) * | 2022-11-10 | 2025-09-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Fused bicyclic compound |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| WO2024173781A1 (en) * | 2023-02-16 | 2024-08-22 | Ohio State Innovation Foundation | Type ii topoisomerase inhibitors and methods of making and using thereof |
| KR20250154499A (ko) * | 2023-03-01 | 2025-10-28 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US12258345B1 (en) | 2023-12-12 | 2025-03-25 | King Faisal University | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| US4446323A (en) | 1983-05-23 | 1984-05-01 | American Home Products Corporation | Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives |
| US5055465A (en) | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| US5166344A (en) | 1989-05-31 | 1992-11-24 | Berlex Laboratories, Inc. | Process for the preparation of imidazoquinoxalinones |
| DE4228095A1 (de) | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
| TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6121278A (en) | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7652014B2 (en) * | 2003-12-10 | 2010-01-26 | Janssen Pharmaceutica | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| AU2005264996A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| AU2005327921A1 (en) | 2004-11-01 | 2006-08-31 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| US7947682B2 (en) | 2004-12-29 | 2011-05-24 | University Of Southern California | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents |
| US20090093489A1 (en) | 2004-12-29 | 2009-04-09 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| WO2006074358A1 (en) * | 2005-01-03 | 2006-07-13 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| GB0615809D0 (en) | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EP2123301A4 (en) | 2006-12-13 | 2010-11-03 | Aska Pharm Co Ltd | Therapeutic agent for urinary tract disease |
| JP5578786B2 (ja) | 2006-12-13 | 2014-08-27 | あすか製薬株式会社 | キノキサリン誘導体 |
| MY165570A (en) | 2006-12-28 | 2018-04-05 | Abbvie Inc | Inhibitors of poly (adp-ribose) polymerase |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| CN101302214B (zh) * | 2007-05-11 | 2012-06-20 | 江苏国华投资有限公司 | 芳烷基哌啶(嗪)衍生物及在治疗精神神经疾病中的应用 |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2010085570A1 (en) * | 2009-01-23 | 2010-07-29 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| US8551996B2 (en) | 2009-02-20 | 2013-10-08 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
-
2010
- 2010-01-21 WO PCT/US2010/021669 patent/WO2010085570A1/en not_active Ceased
- 2010-01-21 KR KR1020117019556A patent/KR101779137B1/ko not_active Expired - Fee Related
- 2010-01-21 EA EA201170963A patent/EA020301B1/ru not_active IP Right Cessation
- 2010-01-21 MX MX2011007741A patent/MX2011007741A/es active IP Right Grant
- 2010-01-21 NZ NZ594322A patent/NZ594322A/xx not_active IP Right Cessation
- 2010-01-21 JP JP2011548104A patent/JP5567599B2/ja not_active Expired - Fee Related
- 2010-01-21 EP EP10703547A patent/EP2389379A1/en not_active Withdrawn
- 2010-01-21 MA MA34106A patent/MA33053B1/fr unknown
- 2010-01-21 US US12/691,668 patent/US7928105B2/en not_active Expired - Fee Related
- 2010-01-21 SG SG2011050630A patent/SG172958A1/en unknown
- 2010-01-21 PE PE2011001360A patent/PE20120418A1/es active IP Right Grant
- 2010-01-21 CA CA2750106A patent/CA2750106A1/en not_active Abandoned
- 2010-01-21 AU AU2010206744A patent/AU2010206744B2/en not_active Ceased
- 2010-01-21 CN CN201080009854.6A patent/CN102341394B/zh not_active Expired - Fee Related
- 2010-01-21 MY MYPI2011003399 patent/MY152386A/en unknown
- 2010-01-21 BR BRPI1007358-2A patent/BRPI1007358A2/pt not_active Application Discontinuation
-
2011
- 2011-03-04 US US13/041,200 patent/US8124606B2/en not_active Expired - Fee Related
- 2011-07-07 IL IL213993A patent/IL213993A/en not_active IP Right Cessation
- 2011-07-08 TN TN2011000339A patent/TN2011000339A1/fr unknown
- 2011-07-19 CL CL2011001754A patent/CL2011001754A1/es unknown
- 2011-07-22 DO DO2011000237A patent/DOP2011000237A/es unknown
- 2011-08-11 CO CO11102248A patent/CO6410305A2/es active IP Right Grant
- 2011-08-23 CR CR20110452A patent/CR20110452A/es unknown
- 2011-08-23 EC EC2011011284A patent/ECSP11011284A/es unknown
-
2012
- 2012-01-18 US US13/352,902 patent/US8450323B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 US US13/889,585 patent/US8822470B2/en not_active Expired - Fee Related
-
2014
- 2014-08-01 US US14/450,101 patent/US9187497B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120418A1 (es) | DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP) | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| MX2010004819A (es) | Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta. | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20161021A1 (es) | Derivados heterociclicos biciclicos como inhibidores de bromodominio | |
| PE20121511A1 (es) | Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa | |
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| PE20191499A1 (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| PE20081346A1 (es) | Derivados de espiroindolinona como antagonistas de mdm2 | |
| AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
| EA201792254A1 (ru) | Малеатные соли ингибитора braf киназы, кристаллические формы, способы их получения и применения | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20142293A1 (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| PE20091335A1 (es) | Derivados de ftalazinona | |
| PE20040593A1 (es) | DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| PE20171342A1 (es) | Compuestos y su uso como inhibidores de bace | |
| PE20160934A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis | |
| PE20120432A1 (es) | Compuestos biciclicos y triciclicos como inhibidores de kat ii | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |